---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-041063"
form_type: "8-K"
ticker: "CERO"
cik: "0001870404"
company_name: "CERO THERAPEUTICS HOLDINGS, INC."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T05:36:12.392540+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Nasdaq Panel finds CERo Therapeutics again compliant with $2.5M equity rule

## Summary
- On May 7, 2025, Nasdaq Hearings Panel determined CERo complied with Listing Rule 5550(b)(1) (minimum $2.5M stockholders' equity).
- Compliance achieved through Series D Preferred private placement (4/21/2025), Equity Line drawdown, and public offering in Feb 2025.
- CEO Chris Ehrlich says company now focused on lead program CER-1236; anticipates first patient dose in Phase 1 trial soon.

## SEC filing metadata
- accession: 0001213900-25-041063
- form_type: 8-K
- ticker: CERO
- cik: 0001870404
- company_name: CERO THERAPEUTICS HOLDINGS, INC.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1870404/000121390025041063/0001213900-25-041063-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1870404/000121390025041063/ea0241411-8k_cero.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-041063
- JSON: https://secwatch.observer/filing/0001213900-25-041063.json
- Plain text: https://secwatch.observer/filing/0001213900-25-041063.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.